Latest Breaking News On - Paulr edick - Page 13 : comparemela.com

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Posted on 7691 Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation is valid in all 27 countries of the European Union, plus Iceland, Norway, and Liechtenstein. As the EC decision was received after the end of the Brexit transition period, Xeris will complete a further administrative step in order to obtain a license in Great Britain. No re-examination of clinical data by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) is expected.

United statesUnited kingdomGreat britainThomas pieberAllison weyGvoke hypopenNovo nordisk glucagenPaulr edickXeris pharmaceuticalsDivision of endocrinologyAmerican diabetes associationEuropean unionPyramid laboratories incCommittee for medicinal products human useXeris pharmaceuticals incDepartment of internal medicine

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United statesThomas pieberAllison weyGvoke hypopenNovo nordisk glucagenPaulr edickDepartment of internal medicineXeris pharmaceuticals incXeris pharmaceuticalsEuropean commissionDivision of endocrinologyAmerican diabetes associationExchange commissionUniversity of grazCorporate communicationsEuropean medicines agency

Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection

News Category Global Banking & Finance Reviews Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it was granted Fast Track designation by the Food and Drug Administration (FDA) for the investigation of XP-0863 (diazepam non-aqueous injection) for the treatment of acute repetitive seizures. Xeris XP-0863 was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet Syndrome.

United statesAllison weyGvoke hypopenPaulr edickExchange commissionXeris pharmaceuticals incCorporate communicationsDrug administrationXeris pharmaceuticalsFast trackXeris chairmanChief executivePrivate securities litigation reform actQuarterly reportVice presidentInvestor relations

Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd to Commercialize Gvoke® in Israel and the Palestinian Authority

Published: Dec 22, 2020 CHICAGO (BUSINESS WIRE) Xeris Pharmaceuticals, Inc.,(Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution agreement with Megapharm Ltd. (“Megapharm”), a leading Israel-based pharmaceutical company, for the commercialization in Israel and the Palestinian Authority of Xeris’ Gvoke® (glucagon injection) for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above. Gvoke® is the world’s first and only ready-to-use liquid glucagon. Under the terms of the agreement, Megapharm will be responsible for registration and marketing of Gvoke® in Israel and the Palestinian Authority, as well as named patient services supply, and Xeris will be responsible for manufacturing, product supply, quality assurance and contr

United statesMiron druckerPaulr edickExchange commissionXeris pharmaceuticals incHealth fundsMegapharm ltdPalestinian authorityAmerican diabetes associationChief executive officerSafety informationAbout severeXeris pharmaceuticalsPrivate securities litigation reform actQuarterly reportஒன்றுபட்டது மாநிலங்களில்